Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors

Blocking CXCLs–CXCR2 axis in tumor–stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment

(2019) Makoto Sano et al.   Oncogenesis

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

(2019) Conan G. Kinsey et al.   NATURE MEDICINE

Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer

(2019) Wantong Yao et al.   NATURE

KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs

(2019) Huiqin Liu et al.   JOURNAL OF CONTROLLED RELEASE

Targeting Tumor Microenvironment for Cancer Therapy

(2019) Catarina Roma-Rodrigues et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

(2019) Wenting Liao et al.   CANCER CELL

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer

(2019) Jessica Konen et al.   Cancers

IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer

(2019) Felix Ritzmann et al.   Scientific Reports

The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment

(2019) Lea Monteran et al.   Frontiers in Immunology

KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer

(2019) Emanuela Pupo et al.   Frontiers in Oncology

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer

(2019) Katsiaryna Marhelava et al.   Cancers

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients

(2018) Alexander T. Falk et al.   LUNG CANCER

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Afatinib restrains K-RAS–driven lung tumorigenesis

(2018) Herwig P. Moll et al.   Science Translational Medicine

The ERBB network facilitates KRAS-driven lung tumorigenesis

(2018) Björn Kruspig et al.   Science Translational Medicine

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

IL22 Promotes Kras -Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties

(2018) Nasim Khosravi et al.   Cancer Immunology Research

Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts

(2018) Linda Ziani et al.   Frontiers in Immunology

The 2018 Nobel Prize in medicine goes to cancer immunotherapy

(2018) Zong Sheng Guo   BMC CANCER

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

(2018) Sandra Misale et al.   CLINICAL CANCER RESEARCH

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis

(2018) Naiara Santana-Codina et al.   Nature Communications

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

(2018) Shunsuke Kitajima et al.   Cancer Discovery

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer

(2017) Daniel Öhlund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1

(2017) N Cohen et al.   ONCOGENE

Drugging RAS: Know the enemy

(2017) Bjoern Papke et al.   SCIENCE

Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer

(2017) Julien Faget et al.   Cell Reports

Tumor Microenvironment and Differential Responses to Therapy

(2017) Eishu Hirata et al.   Cold Spring Harbor Perspectives in Medicine

Synthetic Lethal Vulnerabilities in KRAS -Mutant Cancers

(2017) Andrew J. Aguirre et al.   Cold Spring Harbor Perspectives in Medicine

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

(2017) Edmund Poon et al.   Journal for ImmunoTherapy of Cancer

IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer

(2016) M. S. Caetano et al.   CANCER RESEARCH

Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis

(2016) Michael J. Allegrezza et al.   CANCER RESEARCH

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

(2016) Christopher J. Tape et al.   CELL

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

(2016) Thomas A Mace et al.   GUT

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

RAS isoforms and mutations in cancer at a glance

(2016) G. Aaron Hobbs et al.   JOURNAL OF CELL SCIENCE

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆

(2016) Megan L. Hames et al.   LUNG CANCER

Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma

(2016) A Miller et al.   ONCOGENE

Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis

(2016) Lian-yuan Tao et al.   World Journal of Surgical Oncology

Identification of pyrazolopyridazinones as PDEδ inhibitors

(2016) Björn Papke et al.   Nature Communications

CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer

(2016) Abhilasha Purohit et al.   Oncotarget

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells

(2016) S. Zdanov et al.   Cancer Immunology Research

RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers

(2016) Hidetoshi Sumimoto et al.   PLoS One

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer

(2015) S. Takeuchi et al.   CANCER RESEARCH

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

(2015) J. Downward   CLINICAL CANCER RESEARCH

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome

(2015) Viktor H. Koelzer et al.   Translational Research

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

(2014) Andrew D. Rhim et al.   CANCER CELL

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity

(2014) Ingunn M Stromnes et al.   GUT

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Stromal response to Hedgehog signaling restrains pancreatic cancer progression

(2014) J. J. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T helper 17 cells play a critical pathogenic role in lung cancer

(2014) S. H. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma

(2013) Marjun P. Duldulao et al.   ANNALS OF SURGICAL ONCOLOGY

Loss of the Transcription Factor GLI1 Identifies a Signaling Network in the Tumor Microenvironment Mediating KRAS Oncogene-induced Transformation

(2013) Lisa D. Mills et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells

(2013) Cosimo Commisso et al.   NATURE

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

(2013) Gunther Zimmermann et al.   NATURE

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS -Mutant Lung Cancer

(2013) Ron Chen et al.   Cancer Discovery

KRASp.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer

(2012) Chen Mao et al.   CANCER

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer

(2012) Lauren J. Bayne et al.   CANCER CELL

Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia

(2012) Yuliya Pylayeva-Gupta et al.   CANCER CELL

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers

(2012) Anurag Singh et al.   CELL

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer

(2012) Amanda K. Arrington et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

(2012) Meredith A. Collins et al.   JOURNAL OF CLINICAL INVESTIGATION

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

(2012) N Sunaga et al.   ONCOGENE

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

(2011) M. C. Garassino et al.   ANNALS OF ONCOLOGY

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer

(2011) Noriaki Sunaga et al.   INTERNATIONAL JOURNAL OF CANCER

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma

(2011) Hideaki Ijichi et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice

(2009) Angélica M. Santos et al.   JOURNAL OF CLINICAL INVESTIGATION

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY